Kristin Brooks, Cotract Pharma01.10.20
The growth in targeted therapies for oncology indications is driving demand for highly potent active pharmaceutical ingredients (HPAPIs). For the most part these are small molecule cytotoxic compounds and antibody drug conjugates (ADCs) for cancer indications. Additional therapeutic areas in the HPAPI space include respiratory, hormonal, cardiovascular, and central nervous system disorders, among others.
With more than 20 new oncology therapies launched in the past two years it’s an area that continues to grow for pharmaceutical manufacturers and CMOs. According to MarketWatch, the HPAPI market is expected to exceed more than $28.0 billion by 2024 at a CAGR of 8.5%.
Due to the high level of toxicity, manufacturers must have the appropriate controls, safety equipment, and risk management processes in place to ensure a safe handling and adhere to strict regulatory requirements. Many pharma and biopharma companies opt to outsource to contract manufacturers wi
FREE SUBSCRIPTION
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
